FDA panel to weigh improved booster shots from Moderna, Pfizer
Jun 27, 2022
Both Pfizer and Moderna have been testing updated booster shots that target the omicron variant.
Fourth dose of BNT162b2 prevents severe COVID-19 in nursing home residents
Jun 27, 2022
Substantial protection against hospitalizations and deaths seen among nursing home residents during the omicron surge.
Protection against omicron strongest with hybrid immunity
Jun 17, 2022
Immunity resulting from previous COVID-19 infection and recent booster vaccination confers the strongest protection against the omicron infection.
Veterans report low rates of adverse events with mRNA vaccines
Jun 16, 2022
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.
COVID-19 vaccines cut mortality with heart failure
Jun 16, 2022
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
Vaccine effectiveness against SARS-CoV-2 infection wanes over time
Jun 14, 2022
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Text messaging intervention does not improve COVID-19 vaccine uptake
Jun 13, 2022
No increase in vaccine uptake was seen for individuals receiving text message versus phone calls or for behaviorally informed message content.
Vaccination offers partial protection for postacute phase of COVID-19
May 31, 2022
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
Staff COVID-19 vaccinations have risen 25 percentage points under CMS mandate
By
Kathleen Steele Gaivin
May 18, 2022
COVID-19 vaccination rates among nursing home staff jumped 25 percentage points nationally thanks in no small part to a CMS mandate imposed earlier this year.
Plant-based recombinant COVID-19 vaccine found to be effective
May 04, 2022
Vaccine efficacy ranged from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.